Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study

Kinehara, Yuhei; Matsumoto, Kinnosuke; Shiroyama, Takayuki; Komuta, Kiyohide; Tamiya, Motohiro; Nishino, Kazumi; Tamiya, Akihiro; Kuge, Tomoki; Uchida, Junji; Suzuki, Hidekazu; Yamamoto, Suguru; Tobita, Satoshi; Niki, Toshie; Tetsumoto, Satoshi; Morimura, Osamu; Osa, Akio; Minami, Toshiyuki; Nagatomo, Izumi; Takeda, Yoshito; Kijima, Takashi; Kumanogoh, Atsushi

doi:https://doi.org/10.1016/j.lungcan.2026.109336

Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study

Kinehara, Yuhei; Matsumoto, Kinnosuke; Shiroyama, Takayuki et al.

Lung Cancer, 2026, 214, 109336

アクセス数:117件（2026-06-19 10:11 集計）

固定URL: https://hdl.handle.net/11094/104609

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
LungCancer_214_109336	pdf	なし	1.18 MB	53	2026.04.27

Creative Commons : 表示 - 非営利

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study
著者	著者名 Kinehara, Yuhei
	NRID 1000031030900 1000031030900 ORCID 0000-0002-4930-6997 0000-0002-4930-6997 researchmap permalink kinnosuke.matsumoto kinnosuke.matsumoto Scopus Author ID 57215005043 57215005043 著者名 Matsumoto, Kinnosuke
	NRID 1000060860062 1000060860062 researchmap permalink shiroyama_t shiroyama_t Scopus Author ID 36476578400 36476578400 著者名 Shiroyama, Takayuki
	著者名 Komuta, Kiyohide
	著者名 Tamiya, Motohiro
	著者名 Nishino, Kazumi
	著者名 Tamiya, Akihiro
	著者名 Kuge, Tomoki
	著者名 Uchida, Junji
	著者名 Suzuki, Hidekazu
	著者名 Yamamoto, Suguru
	著者名 Tobita, Satoshi
	著者名 Niki, Toshie
	著者名 Tetsumoto, Satoshi
	著者名 Morimura, Osamu
	著者名 Osa, Akio
	NRID 1000000705113 1000000705113 著者名 Minami, Toshiyuki
	NRID 1000010570583 1000010570583 ORCID 0000-0001-5382-4327 0000-0001-5382-4327 researchmap permalink saxon-w saxon-w Scopus Author ID 13404305500 13404305500 著者名 Nagatomo, Izumi
	NRID 1000040452388 1000040452388 researchmap permalink yoshi10 yoshi10 Scopus Author ID 7404001848 7404001848 著者名 Takeda, Yoshito
	NRID 1000090372614 1000090372614 著者名 Kijima, Takashi
	NRID 1000010294125 1000010294125 ORCID 0000-0003-4749-7117 0000-0003-4749-7117 researchmap permalink read0051725 read0051725 Scopus Author ID 6602726311 6602726311 著者名 Kumanogoh, Atsushi
キーワード等	Ipilimumab
	Nivolumab
	Non-small-cell lung cancer
	Pembrolizumab
	Propensity score
	Real-world
内容	Kinehara Y., Matsumoto K., Shiroyama T., et al. Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study. Lung Cancer 214, 109336 (2026); https://doi.org/10.1016/j.lungcan.2026.109336.
抄録	Background: Nivolumab plus ipilimumab with chemotherapy (NICT) and pembrolizumab with chemotherapy (PCT) are widely used first-line regimens for advanced non–small-cell lung cancer (NSCLC) lacking actionable driver mutations. However, real-world evidence comparing long-term survival outcomes between two regimens, particularly when stratified by PD-L1 tumor proportion score (TPS), remains limited. Methods: We retrospectively analyzed 457 patients treated with NICT or PCT across 13 institutions in Japan between January 2019 and December 2022. Patients were classified into PD-L1 TPS < 1% and ≥ 1% cohorts. Overall survival (OS) and treatment-related adverse events (TRAEs) were assessed using propensity score methods, including inverse probability treatment weighting (IPTW) and overlap weighting (OW), adjusting for 10 clinically relevant covariates. Results: The duration of median follow-up exceeded 40 months. Among 161 patients with PD-L1 TPS < 1% (NICT n = 43; PCT n = 118), NICT achieved significantly longer OS than PCT (median 47.4 versus 16.6 months; IPTW-adjusted hazard ratio 0.50; p = 0.007), with superior 36-month OS rates (51.5% versus 28.2%; p = 0.016). These trends remained robust in the OW sensitivity analysis. In contrast, among 296 patients with PD-L1 TPS ≥ 1% (NICT n = 45; PCT n = 251), no significant differences were observed in median OS or 36-month OS rates between regimens. Grade ≥ 3 TRAEs, treatment discontinuation, and treatment-related death rates were comparable (p = 0.37, 0.78, and 0.32, respectively). Conclusions: NICT provides a sustained long-term survival advantage over PCT with comparable tolerability and may be a promising therapeutic option for the treatment of advanced NSCLC that are PD-L1 negative.
出版者	Elsevier Ireland Ltd
収録物名	Lung Cancer
巻(号)	214
ページ	109336
刊行年月	2026-02-21
言語	英語
ハンドルURL	https://hdl.handle.net/11094/104609
PISSN	01695002
eISSN	18728332
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1016/j.lungcan.2026.109336
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Lung Cancer. 2026, 214, p. 109336
DC.title	Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study
DC.creator	Kinehara, Yuhei
	Matsumoto, Kinnosuke
	Shiroyama, Takayuki
	Komuta, Kiyohide
	Tamiya, Motohiro
	Nishino, Kazumi
	Tamiya, Akihiro
	Kuge, Tomoki
	Uchida, Junji
	Suzuki, Hidekazu
	Yamamoto, Suguru
	Tobita, Satoshi
	Niki, Toshie
	Tetsumoto, Satoshi
	Morimura, Osamu
	Osa, Akio
	Minami, Toshiyuki
	Nagatomo, Izumi
	Takeda, Yoshito
	Kijima, Takashi
	Kumanogoh, Atsushi
DC.publisher	Elsevier Ireland Ltd
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2026-02-21
DC.identifier	https://doi.org/10.1016/j.lungcan.2026.109336
DC.subject	Ipilimumab
	Nivolumab
	Non-small-cell lung cancer
	Pembrolizumab
	Propensity score
	Real-world
DC.description	Kinehara Y., Matsumoto K., Shiroyama T., et al. Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study. Lung Cancer 214, 109336 (2026); https://doi.org/10.1016/j.lungcan.2026.109336.
DCTERMS.abstract	Background: Nivolumab plus ipilimumab with chemotherapy (NICT) and pembrolizumab with chemotherapy (PCT) are widely used first-line regimens for advanced non–small-cell lung cancer (NSCLC) lacking actionable driver mutations. However, real-world evidence comparing long-term survival outcomes between two regimens, particularly when stratified by PD-L1 tumor proportion score (TPS), remains limited. Methods: We retrospectively analyzed 457 patients treated with NICT or PCT across 13 institutions in Japan between January 2019 and December 2022. Patients were classified into PD-L1 TPS < 1% and ≥ 1% cohorts. Overall survival (OS) and treatment-related adverse events (TRAEs) were assessed using propensity score methods, including inverse probability treatment weighting (IPTW) and overlap weighting (OW), adjusting for 10 clinically relevant covariates. Results: The duration of median follow-up exceeded 40 months. Among 161 patients with PD-L1 TPS < 1% (NICT n = 43; PCT n = 118), NICT achieved significantly longer OS than PCT (median 47.4 versus 16.6 months; IPTW-adjusted hazard ratio 0.50; p = 0.007), with superior 36-month OS rates (51.5% versus 28.2%; p = 0.016). These trends remained robust in the OW sensitivity analysis. In contrast, among 296 patients with PD-L1 TPS ≥ 1% (NICT n = 45; PCT n = 251), no significant differences were observed in median OS or 36-month OS rates between regimens. Grade ≥ 3 TRAEs, treatment discontinuation, and treatment-related death rates were comparable (p = 0.37, 0.78, and 0.32, respectively). Conclusions: NICT provides a sustained long-term survival advantage over PCT with comparable tolerability and may be a promising therapeutic option for the treatment of advanced NSCLC that are PD-L1 negative.
DC.rights	This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
DC.format	104609
citation_title	Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study
citation_author	Kinehara, Yuhei
	Matsumoto, Kinnosuke
	Shiroyama, Takayuki
	Komuta, Kiyohide
	Tamiya, Motohiro
	Nishino, Kazumi
	Tamiya, Akihiro
	Kuge, Tomoki
	Uchida, Junji
	Suzuki, Hidekazu
	Yamamoto, Suguru
	Tobita, Satoshi
	Niki, Toshie
	Tetsumoto, Satoshi
	Morimura, Osamu
	Osa, Akio
	Minami, Toshiyuki
	Nagatomo, Izumi
	Takeda, Yoshito
	Kijima, Takashi
	Kumanogoh, Atsushi
citation_publisher	Elsevier Ireland Ltd
citation_language	英語
citation_date	2026-02-21
citation_journal_title	Lung Cancer
citation_volume	214
citation_firstpage	109336
citation_doi	https://doi.org/10.1016/j.lungcan.2026.109336
citation_public_url	https://hdl.handle.net/11094/104609

Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study

閲覧可能ファイル

論文情報

論文詳細を表示